Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Cyclacel Pharmaceuticals reports Q1 EPS ($1.48), consensus (49c) » 16:36
05/12/21
05/12
16:36
05/12/21
16:36
CYCC

Cyclacel Pharmaceuticals

$6.38 /

-0.37 (-5.48%)

As of March 31, cash and…

As of March 31, cash and cash equivalents totaled $47.8M, compared to $33.4M as of December 31, 2020. The increase of $14.4M was primarily due to $18M of net cash provided by financing activities, offset by net cash used in operating activities of $3.6M. There were no revenues for each of the three months ended March 31, 2021 and 2020. "During the quarter, we have made significant progress in bringing our two oral targeted development candidates into mid-stage clinical development. Following recent FDA authorization of our IND for oral fadraciclib, we will finalize contract discussions with sites and open our multi-cohort Phase 1b/2 study in patients with solid tumors," said Spiro Rombotis, president and CEO. "We believe fadraciclib is establishing a strong position among compounds in clinical development that specifically address cancer resistance mechanisms, including suppression of MCL1, MYC and cyclin E. A recent publication identified potential utility of CDK9 inhibitors in KRAS mutant colorectal cancer, one of the tumor types in our study. Together with our oral CYC140 PLK1 inhibitor program, which has shown in preclinical models that KRAS mutant cancers are sensitive to CYC140 inhibition, we hope to provide valuable alternatives to patients with these difficult to treat malignancies. After strengthening our balance sheet in the quarter, we are executing a precision medicine strategy to achieve multiple milestones and data read outs over the next two years."

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$6.38 /

-0.37 (-5.48%)

CYCC Cyclacel Pharmaceuticals
$6.38 /

-0.37 (-5.48%)

04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
  • 12
    Mar
CYCC Cyclacel Pharmaceuticals
$6.38 /

-0.37 (-5.48%)

Initiation
Fly Intel: Top five analyst initiations » 09:56
04/30/21
04/30
09:56
04/30/21
09:56
DKNG

DraftKings

$57.33 /

-0.115 (-0.20%)

, SIOX

Sio Gene Therapies

$2.87 /

+0.17 (+6.30%)

, NRIX

Nurix Therapeutics

$34.84 /

+ (+0.00%)

, CYCC

Cyclacel Pharmaceuticals

$7.35 /

+0.25 (+3.52%)

, CSTL

Castle Biosciences

$67.90 /

-0.19 (-0.28%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DraftKings (DKNG) initiated with a Buy at Guggenheim. 2. Sio Gene Therapies (SIOX) initiated with a Buy at H.C. Wainwright. 3. Nurix Therapeutics (NRIX) initiated with an Outperform at RBC Capital. 4. Cyclacel Pharmaceuticals (CYCC) initiated with an Outperform at Oppenheimer. 5. Castle Biosciences (CSTL) initiated with a Buy at Lake Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SIOX Sio Gene Therapies
$2.87 /

+0.17 (+6.30%)

NRIX Nurix Therapeutics
$34.84 /

+ (+0.00%)

DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

CYCC Cyclacel Pharmaceuticals
$7.35 /

+0.25 (+3.52%)

CSTL Castle Biosciences
$67.90 /

-0.19 (-0.28%)

DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

04/30/21 Guggenheim
Guggenheim starts DraftKings with Buy on 'significant share' opportunity
04/30/21 Guggenheim
DraftKings initiated with a Buy at Guggenheim
04/26/21 Needham
DraftKings initiated with a Buy at Needham
04/07/21 Truist
Truist sees NY budget agreement's mobile sports betting deal as 'clear as mud'
SIOX Sio Gene Therapies
$2.87 /

+0.17 (+6.30%)

04/30/21 H.C. Wainwright
Sio Gene Therapies initiated with a Buy at H.C. Wainwright
NRIX Nurix Therapeutics
$34.84 /

+ (+0.00%)

04/30/21 RBC Capital
Nurix Therapeutics initiated with an Outperform at RBC Capital
04/30/21 RBC Capital
Nurix Therapeutics initiated with an Outperform at RBC Capital
04/30/21 Piper Sandler
Nurix Therapeutics assumed with an Overweight at Piper Sandler
04/14/21 Berenberg
Nurix Therapeutics initiated with a Buy at Berenberg
CYCC Cyclacel Pharmaceuticals
$7.35 /

+0.25 (+3.52%)

04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
CSTL Castle Biosciences
$67.90 /

-0.19 (-0.28%)

04/30/21 Lake Street
Castle Biosciences initiated with a Buy at Lake Street
03/09/21 Baird
Castle Biosciences price target lowered to $82 from $87 at Baird
02/03/21 KeyBanc
Castle Biosciences price target raised to $90 from $70 at KeyBanc
01/26/21 Canaccord
Castle Biosciences price target raised to $84 from $80 at Canaccord
SIOX Sio Gene Therapies
$2.87 /

+0.17 (+6.30%)

NRIX Nurix Therapeutics
$34.84 /

+ (+0.00%)

DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

CYCC Cyclacel Pharmaceuticals
$7.35 /

+0.25 (+3.52%)

CSTL Castle Biosciences
$67.90 /

-0.19 (-0.28%)

  • 12
    Mar
  • 05
    Mar
  • 16
    Dec
  • 07
    Oct
  • 24
    Jul
  • 25
    Jun
  • 19
    Jun
DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

SIOX Sio Gene Therapies
$2.87 /

+0.17 (+6.30%)

DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

CSTL Castle Biosciences
$67.90 /

-0.19 (-0.28%)

SIOX Sio Gene Therapies
$2.87 /

+0.17 (+6.30%)

NRIX Nurix Therapeutics
$34.84 /

+ (+0.00%)

DKNG DraftKings
$57.33 /

-0.115 (-0.20%)

CYCC Cyclacel Pharmaceuticals
$7.35 /

+0.25 (+3.52%)

Initiation
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer » 06:24
04/30/21
04/30
06:24
04/30/21
06:24
CYCC

Cyclacel Pharmaceuticals

$7.12 /

-0.08 (-1.11%)

Oppenheimer analyst Kevin…

Oppenheimer analyst Kevin DeGeeter initiated coverage of Cyclacel Pharmaceuticals with an Outperform rating and $17 price target, citing the potential of fadraciclib CDK2/9 inhibitor in treatment of MCL-1 dependent tumors, the expectation for oral formulation of fadraciclib to support timely enrollment for expansion cohorts in solid tumor and hematology populations, an improved AE profile with oral vs. IV, and the opportunity for CYC140 differentiation from other PLK1 inhibitors based on single agent development path. DeGeeter views fadraciclib as a potential first-in-class opportunity and believes Cyclacel can fund operations into 1H23, the analyst tells investors in a research note.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

  • 12
    Mar
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

Initiation
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer » 16:11
04/29/21
04/29
16:11
04/29/21
16:11
CYCC

Cyclacel Pharmaceuticals

$7.12 /

-0.08 (-1.11%)

Oppenheimer analyst Kevin…

Oppenheimer analyst Kevin DeGeeter initiated coverage of Cyclacel Pharmaceuticals with an Outperform rating and $17 price target.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

  • 12
    Mar
CYCC Cyclacel Pharmaceuticals
$7.12 /

-0.08 (-1.11%)

Options
new option listings and three option delistings on April 21st » 08:30
04/21/21
04/21
08:30
04/21/21
08:30
APP

AppLovin

$60.40 /

+1.71 (+2.91%)

, BSPE

Bespoke Capital Acquisition

$10.08 /

+0.09 (+0.90%)

, CFB

CrossFirst Bancshares

$13.38 /

-0.27 (-1.98%)

, CHRA

Charah Solutions

$5.67 /

-0.47 (-7.65%)

, CTEC

Cholestech

$19.97 /

-0.63 (-3.06%)

, CYCC

Cyclacel Pharmaceuticals

$6.40 /

-0.11 (-1.69%)

, DFNS

LGL Systems Acquisition Corp.

$9.90 /

-0.04 (-0.40%)

, FARM

Farmer Bros.

$9.98 /

-0.29 (-2.82%)

, FSTX

F-star Therapeutics

$9.48 /

-0.28 (-2.87%)

, GENI

Genius Sports

$16.23 /

-2.025 (-11.09%)

, GNPK

Genesis Park Acquisition

$10.13 /

-0.06 (-0.59%)

, IDEV

Indevus

$66.33 /

-1.07 (-1.59%)

, INFU

InfuSystem

$21.63 /

-0.17 (-0.78%)

, JOAN

Joann

$11.37 /

-0.02 (-0.18%)

, MAX

MediaAlpha

$32.98 /

-1.76 (-5.07%)

, NVVE

Nuvve Holding

$8.59 /

-0.47 (-5.19%)

, OBLG

Oblong

$4.14 /

-0.19 (-4.39%)

, PSI

PSI Technologies Holdings, Inc.

$119.80 /

-2 (-1.64%)

, SCPH

scPharmaceuticals

$6.28 /

-0.13 (-2.03%)

, SMIN

Southern Mineral Corp

$45.90 /

-0.545 (-1.17%)

, SNSR

Control Devices

$33.59 /

-0.7 (-2.04%)

, WKEY

WISeKey

$8.45 /

-0.28 (-3.21%)

, XFOR

X4 Pharmaceuticals

$9.00 /

-0.3 (-3.23%)

, ZKIN

ZK International Group

$5.32 /

-0.19 (-3.45%)

, CBPO

China Biologic

$119.98 /

+2.2 (+1.87%)

, DMYD

dMY Technology II

/

+

, IPHI

Inphi

$172.33 /

-1.85 (-1.06%)

New option listings for…

New option listings for April 21st include First Trust RBA American Industrial Renaissance (AIRR), Applovin Corporation (Class A Stock) (APP), Bespoke Capital Acquisition Corporation (Class A Stock) (BSPE), CrossFirst Bankshares Inc (CFB), Charah Solutions Inc (CHRA), Global X CleanTech ETF (CTEC), Cyclacel Pharmaceuticals (CYCC), LGL Systems Acquisition Corp (Class A Stock) (DFNS), iShares Emerging Markets Dividend (DVYE), iShares MSCI Emerging Markets Asia (EEMA), Farmer Bros. (FARM), F star Therapeutics Inc (FSTX), First Trust Nasdaq Oil and Gas (FTXN), First Trust Nasdaq Bank (FTXO), First Trust Nasdaq Transportation (FTXR), First Trust Small Cap Core AlphaDEX Fund (FYX), Genius Sports Limited (GENI), Genesis Park Acquisition Corp (Class A Stock) (GNPK), iShares Core MSCI International Developed Markets ETF (IDEV), InfuSystem (INFU), iShares Russell Top 200 Growth (IWY), iShares US Consumer Services (IYC), iShares US Consumer Goods (IYK), JOANN Inc (JOAN), MediaAlpha Inc (Class A Stock) (MAX), Nuvve Holding Corporation (NVVE), Oblong Inc (OBLG), PowerShares Dynamic Semiconductors Portfolio (PSI), scPharmaceuticals Inc (SCPH), iShares MSCI India Small Cap ETF (SMIN), Global X Internet of Things Thematic (SNSR), Soaring Eagle Acquisition Corporation (Units) (SRNGU), iShares Core US REIT ETF (USRT), Vanguard International Dividend Appreciation ETN (VIGI), WISeKey International Holdings SA (ADR) (WKEY), X4 Pharmaceuticals Inc (XFOR), and ZK International Group Co Ltd (ZKIN). Option delistings effective April 21st include China Bioligic Products Holdings Inc (CBPO), dMY Technology Group Inc II (Class A Stock) (DMYD), and Inphi Corporation (IPHI).

ShowHide Related Items >><<
ZKIN ZK International Group
$5.32 /

-0.19 (-3.45%)

XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

WKEY WISeKey
$8.45 /

-0.28 (-3.21%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

OBLG Oblong
$4.14 /

-0.19 (-4.39%)

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

DMYD dMY Technology II
/

+

DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

CHRA Charah Solutions
$5.67 /

-0.47 (-7.65%)

CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

APP AppLovin
$60.40 /

+1.71 (+2.91%)

BSPE Bespoke Capital Acquisition
$10.08 /

+0.09 (+0.90%)

04/21/21 Telsey Advisory
Bespoke Capital Acquisition initiated with an Outperform at Telsey Advisory
04/21/21 Telsey Advisory
Bespoke Capital Acquisition initiated with an Outperform at Telsey Advisory
CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

03/08/21 Truist
CrossFirst Bancshares price target raised to $15 from $12 at Truist
12/07/20 Raymond James
CrossFirst Bancshares upgraded to Outperform from Market Perform at Raymond James
12/07/20 Raymond James
CrossFirst upgraded to Outperform from Market Perform at Raymond James
07/20/20 Truist
CrossFirst Bancshares initiated with a Hold at SunTrust
CHRA Charah Solutions
$5.67 /

-0.47 (-7.65%)

CTEC Cholestech
$19.97 /

-0.63 (-3.06%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

03/31/21 B. Riley
B. Riley upgrades Farmer Bros. to Buy with recovery 'turning a corner'
03/31/21 B. Riley
Farmer Bros. upgraded to Buy from Neutral at B. Riley Securities
02/08/21 Roth Capital
Farmer Bros. price target raised to $7 from $6 at Roth Capital
01/08/21 B. Riley
Farmer Bros. price target raised to $4.50 from $4 at B. Riley Securities
FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
GENI Genius Sports
$16.23 /

-2.025 (-11.09%)

02/23/21 Benchmark
dMY Technology II initiated with a Buy at Benchmark
GNPK Genesis Park Acquisition
$10.13 /

-0.06 (-0.59%)

IDEV Indevus
$66.33 /

-1.07 (-1.59%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

12/29/20 Sidoti
InfuSystem initiated with a Buy at Sidoti
08/31/20
Fly Intel: Top five analyst initiations
08/31/20 Craig-Hallum
InfuSystem initiated with a Buy at Craig-Hallum
06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
JOAN Joann
$11.37 /

-0.02 (-0.18%)

04/06/21 William Blair
Joann initiated with an Outperform at William Blair
04/06/21 BofA
BofA starts Joann at Buy with $27 price target
04/06/21 Wells Fargo
Joann initiated with an Overweight at Wells Fargo
04/06/21 Guggenheim
Joann initiated with a Buy at Guggenheim
MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

03/12/21 Canaccord
MediaAlpha price target raised to $75 from $54 at Canaccord
03/12/21 RBC Capital
MediaAlpha price target raised to $65 from $50 at RBC Capital
12/11/20 Canaccord
MediaAlpha expected to be part of any insurance marketing, says Canaccord
12/08/20
Fly Intel: Top five analyst initiations
NVVE Nuvve Holding
$8.59 /

-0.47 (-5.19%)

04/19/21 Craig-Hallum
Nuvve Holding initiated with a Buy at Craig-Hallum
OBLG Oblong
$4.14 /

-0.19 (-4.39%)

PSI PSI Technologies Holdings, Inc.
$119.80 /

-2 (-1.64%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

12/08/20 BMO Capital
scPharmaceuticals price target lowered to $10 from $13 at BMO Capital
05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
SMIN Southern Mineral Corp
$45.90 /

-0.545 (-1.17%)

SNSR Control Devices
$33.59 /

-0.7 (-2.04%)

WKEY WISeKey
$8.45 /

-0.28 (-3.21%)

09/09/20 H.C. Wainwright
WISeKey price target raised to $9 from $6 at H.C. Wainwright
XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
ZKIN ZK International Group
$5.32 /

-0.19 (-3.45%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

DMYD dMY Technology II
/

+

04/07/21 Craig-Hallum
Craig-Hallum sees Genius as 'a clear winner' after NY online sports betting news
04/05/21 Craig-Hallum
Genius Sports price target raised to $30 from $25 at Craig-Hallum
02/25/21 B. Riley
B. Riley starts dMY at Buy as better way to invest in sports betting
02/24/21 B. Riley
dMY Technology II initiated with a Buy at B. Riley Securities
IPHI Inphi
$172.33 /

-1.85 (-1.06%)

03/24/21 Stifel
Chinese approval for Inphi deal 'highly favorable' for Marvell, says Stifel
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
02/09/21 Barclays
Inphi downgraded to Equal Weight from Overweight at Barclays
XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

  • 15
    Apr
  • 19
    Mar
  • 12
    Mar
  • 12
    Mar
  • 28
    Oct
  • 21
    May
IPHI Inphi
$172.33 /

-1.85 (-1.06%)

DMYD dMY Technology II
/

+

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

GNPK Genesis Park Acquisition
$10.13 /

-0.06 (-0.59%)

GENI Genius Sports
$16.23 /

-2.025 (-11.09%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

DMYD dMY Technology II
/

+

DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

APP AppLovin
$60.40 /

+1.71 (+2.91%)

DMYD dMY Technology II
/

+

Over a quarter ago
Syndicate
Cyclacel Pharmaceuticals 1.807M share Spot Secondary priced at $7.00 » 08:33
03/12/21
03/12
08:33
03/12/21
08:33
CYCC

Cyclacel Pharmaceuticals

$7.82 /

+0.66 (+9.22%)

Oppenheimer acted as lead…

Oppenheimer acted as lead book running manager for the offering.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$7.82 /

+0.66 (+9.22%)

CYCC Cyclacel Pharmaceuticals
$7.82 /

+0.66 (+9.22%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$7.82 /

+0.66 (+9.22%)

  • 12
    Mar
Syndicate
Cyclacel Pharmaceuticals files to sell common stock, no amount given » 16:02
03/11/21
03/11
16:02
03/11/21
16:02
CYCC

Cyclacel Pharmaceuticals

$7.86 /

+0.7 (+9.78%)

Oppenheimer & Co.…

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the public offering.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$7.86 /

+0.7 (+9.78%)

CYCC Cyclacel Pharmaceuticals
$7.86 /

+0.7 (+9.78%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$7.86 /

+0.7 (+9.78%)

Hot Stocks
Cyclacel Pharmaceuticals announces 2021 key business objectives » 08:42
01/11/21
01/11
08:42
01/11/21
08:42
CYCC

Cyclacel Pharmaceuticals

$8.91 /

+0.81 (+10.00%)

Key Business Objectives…

Key Business Objectives for 2021: First patient dosed with oral fadraciclib in Phase 1/2 advanced solid tumor study; First patient dosed with oral CYC140 in Phase 1/2 advanced solid tumor study; Manufacture clinical supplies of fadraciclib and CYC140 for registration-enabling studies; Data on safety and antileukemic activity from the i.v. fadraciclib-venetoclax Phase 1 study in relapsed/refractory AML and CLL; Data from the sapacitabine-venetoclax Phase 1/2 study in relapsed/refractory AML or MDS; Initial data from the CYC140 Phase 1 First-in-Human study in patients with advanced leukemias; Data from the Phase 1b/2 IST of sapacitabine-olaparib combination in patients with BRCA mutant metastatic breast cancer when reported by the investigators.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

Hot Stocks
Cyclacel Pharmaceuticals expects capital to fund operations to early 2023 » 08:41
01/11/21
01/11
08:41
01/11/21
08:41
CYCC

Cyclacel Pharmaceuticals

$8.91 /

+0.81 (+10.00%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals provided a business update reviewing 2020 achievements and outlining the Company's key business objectives for 2021. The Company will present at Biotech Showcase Digital 2021 taking place virtually from January 11 to 15 with a prerecorded session of the company presentation. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors and industry stakeholders during the event. Registered Biotech Showcase Digital 2021 attendees may request one-on-one meetings with Cyclacel through the partneringONE system. 2020 Key Achievements: Data from Phase 1 study of fadraciclib as a single agent reported at the Plenary Session of the 32nd EORTC-NCI-AACR Symposium; Radiographically confirmed partial response after a month and a half on i.v. fadraciclib: MCL1-amplified endometrial cancer; failed seven lines of prior therapy; continuing treatment for more than 16 months with 96% reduction in target tumor lesions; High bioequivalence observed in 5 patients treated with oral fadraciclib; Enrolled 19 patients evaluating i.v. fadraciclib in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL with evidence of antileukemic activity; Enrolled five patients evaluating i.v. CYC140 in patients with advanced leukemias; Enrolled 12 patients in Phase 1/2 study evaluating an oral regimen of sapacitabine in combination with venetoclax in patients with relapsed or refractory AML/MDS; Announced peer-reviewed publication of a fadraciclib review in PLOS ONE. Authored by scientists from Cyclacel and The Institute of Cancer Research, London, the publication describes the discovery of fadraciclib and shows that its targeting of CDK2 and CDK9 leads to broad therapeutic potential Appointed Mark Kirschbaum, M.D. as Senior Vice President and Chief Medical Officer. Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care; Appointed Brian Schwartz, M.D, formerly CMO at ArQule, Inc., and Karin L. Walker, Chief Accounting Officer of Prothena Corporation plc, to the Board of Directors; Raised approximately $30 million in net cash in two equity financings and related warrant exercises providing estimated capital to early 2023. In 2021, Cyclacel will commence streamlined Phase 1/2 clinical studies, initially of oral fadraciclib and subsequently of oral CYC140, in a broad range of solid tumors and hematological malignancies. These studies are supported by fadraciclib's Phase 1 clinical data and its transcriptional mechanism of action enabling apoptosis of cancer cells and the extensive preclinical data of CYC140 demonstrating its antimitotic mechanism and broad therapeutic potential in several solid tumors and hematological malignancies. The clinical development plan for these studies calls for parallel evaluation of different schedules of the two agents in multiple cohorts defined by cancer histology and collection of biospecimens for translational analysis. The aim of these studies is to identify clinical activity which may lead to registration-enabling studies.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$8.91 /

+0.81 (+10.00%)

Hot Stocks
Cyclacel Pharmaceuticals announces $7M investment by Acorn Bioventures » 08:09
12/22/20
12/22
08:09
12/22/20
08:09
CYCC

Cyclacel Pharmaceuticals

$4.28 /

+0.04 (+0.94%)

Cyclacel Pharmaceuticals…

Cyclacel Pharmaceuticals announced it has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. Under the agreement, Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock, and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7M. The offering is priced at-the-market pursuant to the rules of The Nasdaq Stock Market. The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share. Cyclacel intends to use substantially all of the net proceeds of approximately $6.9M from the registered direct offering and concurrent private placement to rapidly advance clinical development of CYC140, a Polo-like-kinase 1 inhibitor.

ShowHide Related Items >><<
CYCC Cyclacel Pharmaceuticals
$4.28 /

+0.04 (+0.94%)

CYCC Cyclacel Pharmaceuticals
$4.28 /

+0.04 (+0.94%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
CYCC Cyclacel Pharmaceuticals
$4.28 /

+0.04 (+0.94%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.